Google
NTRB — NUTRIBAND INC (Healthcare >> Biotechnology)
NTRB FAQ
What is NTRB's ROE?
NUTRIBAND INC reports a Return on Equity (ROE) of -123.21%.
What is NTRB's dividend yield?
NUTRIBAND INC offers a dividend yield of 0.00%.
What is NTRB's Deepscope Quality Score?
Deepscope rates NTRB's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NTRB?
Deepscope's AI Timing Score for NTRB is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NTRB belong to?
NUTRIBAND INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.51
Price
-0.04
(-1.13%)
Day Change
|
|
|---|
NTRB, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 74 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.51 |
| PBV / Sector |
6.39 / 4.48
|
| Earning Per Share | -0.71 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.04 M
GREAT
|
| Average 1W Daily Value |
0.05 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:24:18 |
| Symbol | NTRB |
| Name | NUTRIBAND INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 12.16 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 42.67 / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 121 South Orange Avenue, Orlando, FL, United States, 32801
Phone: 407 377 6695
Website: https://www.nutriband.com
Sector: Healthcare >> Biotechnology
Description: Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
